Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Identifying the need for neoadjuvant chemotherapy in stage I breast cancer

Manon De Graaf • 14 Sep 2024
ESMO 2024
Breast Cancer

Manon De Graaf, MD, Netherlands Cancer Institute, Amsterdam, The Netherlands, comments which patients with stage I triple-negative breast cancer (TNBC) truly require neoadjuvant chemotherapy. Given the typically good prognosis for patients with stage I TNBC, it is crucial to accurately identify those who will benefit from chemotherapy to avoid unnecessary treatment while ensuring optimal outcomes for those in need. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Manon De Graaf

The role of immune biomarkers in guiding breast cancer treatment decisions
0:29
The role of immune biomarkers in guiding breast cancer treatment decisions
Manon De Graaf • 14 Sep 2024
pCR and survival after neoadjuvant chemotherapy in stage I TNBC: a registry-based study
1:02
pCR and survival after neoadjuvant chemotherapy in stage I TNBC: a registry-based study
Manon De Graaf • 14 Sep 2024
Evaluating the role of neoadjuvant chemotherapy and surgery in stage I TNBC
1:02
Evaluating the role of neoadjuvant chemotherapy and surgery in stage I TNBC
Manon De Graaf • 14 Sep 2024

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals